Clinical safety rating: safe
Inhaled corticosteroid (ICS) for persistent asthma. The most studied ICS in pregnancy; large registry data (>2,500 exposures) confirm no increase in congenital malformations. Preferred ICS to initiate in pregnancy due to available safety data, though other ICS are considered acceptable. Systemic absorption from inhaled use is minimal. Uncontrolled asthma poses greater risk than ICS treatment.
Budesonide is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and chemokines, and suppression of airway inflammation.
| Metabolism | Primarily metabolized by cytochrome P450 3A4 (CYP3A4) in the liver and intestinal mucosa to 16α-hydroxyprednisolone and 6β-hydroxybudesonide, which have negligible glucocorticoid activity. |
| Excretion | Primarily hepatic metabolism via CYP3A4; metabolites are excreted in urine (~60%) and feces (~40%). Less than 10% of unchanged drug is recovered in urine. |
| Half-life | Terminal elimination half-life is 2-3 hours in adults, reflecting rapid clearance. Clinical context: duration of anti-inflammatory effect may exceed half-life due to receptor binding. |
| Protein binding | 85-90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 2.3-4.2 L/kg, indicating extensive tissue distribution. High Vd reflects lipophilicity and partitioning into tissues. |
| Bioavailability | Inhaled: Approximately 10-20% of the dose reaches the lungs; oral bioavailability of swallowed fraction is <1% due to extensive first-pass metabolism. |
| Onset of Action | Inhaled: Therapeutic effect on asthma symptoms begins within 24-48 hours, but maximal improvement may take 1-2 weeks of regular use. |
| Duration of Action | Inhaled: Duration of bronchodilator effect is 12-24 hours with twice-daily dosing; clinical anti-inflammatory effect persists with regular dosing. |
| Molecular Weight | 430.53 |
200-800 mcg twice daily via inhalation. Maximum 1600 mcg/day.
| Renal impairment | No dose adjustment required. |
| Liver impairment | Caution in severe hepatic impairment (Child-Pugh C); consider dose reduction due to increased systemic exposure. |
| Pediatric use | Children 6-15 years: 200-400 mcg twice daily. Children <6 years: 200-400 mcg twice daily via nebulizer or MDI with spacer. |
| Geriatric use | No specific dose adjustment; use lowest effective dose due to potential for increased systemic effects. |
| 1st trimester | Inhaled budesonide is not associated with an increased risk of major malformations; it is the preferred inhaled corticosteroid during pregnancy due to extensive safety data. |
| 2nd trimester | No increased risk of adverse fetal outcomes; continued use is recommended for asthma control. |
| 3rd trimester | Use is considered safe; adequate asthma control is important to prevent maternal hypoxemia and fetal compromise. |
Clinical note
Inhaled corticosteroid (ICS) for persistent asthma. The most studied ICS in pregnancy; large registry data (>2,500 exposures) confirm no increase in congenital malformations. Preferred ICS to initiate in pregnancy due to available safety data, though other ICS are considered acceptable. Systemic absorption from inhaled use is minimal. Uncontrolled asthma poses greater risk than ICS treatment.
| Placental transfer | Budesonide undergoes extensive first-pass metabolism; systemic bioavailability after inhalation is low (approximately 10-30% of the dose). The degree of placental transfer is minimal due to low maternal plasma concentrations. |
■ FDA Black Box Warning
No FDA black box warning for inhaled budesonide.
| Serious Effects |
Hypersensitivity to budesonide or any component of the formulationStatus asthmaticus (primary treatment)
| Precautions | May cause systemic corticosteroid effects, particularly at high doses or prolonged use (e.g., adrenal suppression, Cushing's syndrome)., Increased risk of pneumonia in patients with COPD., Potential for oropharyngeal candidiasis and hoarseness; rinse mouth after use., May reduce growth velocity in pediatric patients; monitor growth regularly., Avoid abrupt discontinuation in patients transitioning from systemic corticosteroids to inhaled budesonide; risk of adrenal insufficiency., Use with caution in patients with active or quiescent tuberculosis, fungal, bacterial, viral, or parasitic infections. |
| Food/Dietary | No significant food interactions. Grapefruit juice may increase systemic exposure but is unlikely to be relevant with inhaled route. Avoid eating immediately after inhalation to reduce oropharyngeal deposition. |
Loading safety data…
| Breastfeeding |
| Inhaled budesonide has minimal systemic absorption and is not expected to cause adverse effects in breastfed infants. It is considered compatible with breastfeeding. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Inhaled budesonide is not associated with a significant increase in congenital malformations. Data from large cohort studies show no increased risk of major birth defects with first-trimester use. However, high systemic exposure may occur with high doses; minimal systemic absorption limits risk. No known fetal toxicity in second or third trimesters. |
| Fetal Monitoring | Monitor asthma control (peak expiratory flow, symptoms, exacerbations). No specific fetal monitoring required beyond routine prenatal care. Assess growth if high systemic doses used. |
| Fertility Effects | No known adverse effects on fertility. Inhaled budesonide does not impair male or female fertility based on animal studies and clinical data. |
| Clinical Pearls | Rinse mouth with water (not swallow) after each use to prevent oral candidiasis and dysphonia. When transitioning from oral corticosteroids, taper slowly and monitor for adrenal insufficiency. In acute exacerbations, consider systemic corticosteroids; inhaled budesonide is not for acute bronchospasm. Use with spacer device improves lung deposition and reduces oropharyngeal side effects. |
| Patient Advice | Do not use for sudden breathing problems; it is a maintenance therapy. · Rinse mouth with water after each use and spit out, do not swallow. · Use your inhaler exactly as prescribed; do not stop without consulting your doctor. · Shake inhaler well before use (if suspension) and prime if not used for >1 week. · Keep track of your doses; know when to refill. · If you use a spacer, follow instructions for proper use. · Report any signs of oral thrush (white patches in mouth) or hoarseness to your doctor. · Carry a rescue inhaler (e.g., albuterol) for acute symptoms. |